EE+ POEM Archive
Oral fingolimod reduces MS recurrence, appears to increase cancer risk
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "Oral Fingolimod Reduces MS Recurrence, Appears to Increase Cancer Risk." EE+ POEM Archive, John Wiley & Sons, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/427000/all/Oral_fingolimod_reduces_MS_recurrence__appears_to_increase_cancer_risk.
Oral fingolimod reduces MS recurrence, appears to increase cancer risk. In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2019. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/427000/all/Oral_fingolimod_reduces_MS_recurrence__appears_to_increase_cancer_risk. Accessed October 9, 2024.
Oral fingolimod reduces MS recurrence, appears to increase cancer risk. (2019). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/427000/all/Oral_fingolimod_reduces_MS_recurrence__appears_to_increase_cancer_risk
Oral Fingolimod Reduces MS Recurrence, Appears to Increase Cancer Risk [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2019. [cited 2024 October 09]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/427000/all/Oral_fingolimod_reduces_MS_recurrence__appears_to_increase_cancer_risk.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Oral fingolimod reduces MS recurrence, appears to increase cancer risk
ID - 427000
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/427000/all/Oral_fingolimod_reduces_MS_recurrence__appears_to_increase_cancer_risk
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
